Invention Grant
- Patent Title: Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
-
Application No.: US16730020Application Date: 2019-12-30
-
Publication No.: US11241424B2Publication Date: 2022-02-08
- Inventor: Chan-Jung Li , David Chih-Kuang Chou , Jin-Ding Huang , Shin-Jr Tsai , Shu-Wen Kuo , Yu-En Tien
- Applicant: LUMOSA THERAPEUTICS CO., LTD. , SHANGHAI LUMOSA THERAPEUTICS CO., LTD.
- Applicant Address: TW Taipei; CN Shanghai
- Assignee: LUMOSA THERAPEUTICS CO., LTD.,SHANGHAI LUMOSA THERAPEUTICS CO., LTD.
- Current Assignee: LUMOSA THERAPEUTICS CO., LTD.,SHANGHAI LUMOSA THERAPEUTICS CO., LTD.
- Current Assignee Address: TW Taipei; CN Shanghai
- Agency: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
- Main IPC: A61K31/485
- IPC: A61K31/485 ; A61K47/44 ; A61K47/14 ; A61K9/00

Abstract:
The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as manufacturing processes and medical uses of the formulations. The invention further provides methods for adjusting the duration of action of the formulations by varying the ratio of the pharmaceutically acceptable oil and the oil-miscible retaining solvent.
Public/Granted literature
- US20200179372A1 PHARMACEUTICAL FORMULATIONS FOR SUSTAINED RELEASE OF SEBACOYL DINALBUPHINE ESTER Public/Granted day:2020-06-11
Information query
IPC分类: